Vascular effects of [Arg8]vasopressin in the isolated perfused rat kidney

European Journal of Pharmacology
M BarthelmebsJ L Imbs

Abstract

The renal vascular effects of [Arg8]vasopressin (vasopressin) were investigated in the isolated perfused rat kidney. Vasopressin (0.01-3 nM) elicited a dose-dependent vasoconstriction in kidneys from Sprague Dawley rats, with a EC50 value of 0.206 +/- 0.044 nM. Inhibition of nitric oxide synthase by N omega-nitro-L-arginine (100 microM) shifted the vasopressin-induced vasoconstrictor response curve to the left. Inhibition of cyclooxygenase by indomethacin (10 or 30 microM) blunted the constriction induced by low concentrations of the peptide. Vasopressin, like angiotensin II but not noradrenaline, induced tachyphylaxis, SR 49059 ((2S)1-[(2R,3S)-5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxybenzene- sulfonyl)-3-hydroxy-2,3-dihydro-1H-indole-2-carbonyl]-pyrrolidine-2- carboxamide) (1-30 nM), a new potent and selective non-peptide vasopressin V1A receptor antagonist, shifted the concentration-response curve for vasopressin to the right without decreasing the maximum contraction. Antagonism became competitive with a pA2 value (+/- S.D.) of 9.72 +/- 0.20 during inhibition of nitric oxide release. [Mpa1,D-Arg8]Vasopressin (desmopressin; 0.1-100 nM), or vasopressin (0.01-1 nM) after blockade of the vasopressin V1A receptor by SR 49059, ...Continue Reading

References

Oct 1, 1988·Physiological Reviews·L Share
Jul 1, 1988·Neuroscience and Behavioral Physiology·S V Verevkina
Jan 1, 1987·Pharmacology·Z Katusić, M K Krstić
May 1, 1967·The American Journal of Medicine·H D Lauson
Sep 1, 1980·Journal of Cardiovascular Pharmacology·M Schmidt, J L Imbs
Jan 1, 1984·Journal of Cardiovascular Pharmacology·K G HofbauerR Stalder
Nov 1, 1984·Circulation Research·Z S KatusicP M Vanhoutte
Feb 1, 1984·Circulation Research·A W CowleyB J Barber
Apr 1, 1981·The Journal of Clinical Investigation·G A AisenbreyR W Schrier
Feb 1, 1994·Journal of Cardiovascular Pharmacology·Y AkiY Abe
Oct 1, 1994·British Journal of Pharmacology·M C MartínezS Lluch
Mar 1, 1993·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·M TakayasuH Hidaka
Jan 1, 1993·Annual Review of Pharmacology and Toxicology·A M Lefer, D J Lefer
Dec 1, 1995·Journal of Cardiovascular Pharmacology·D StephanM Barthelmebs
Mar 1, 1959·British Journal of Pharmacology and Chemotherapy·O ARUNLAKSHANA, H O SCHILD

❮ Previous
Next ❯

Citations

Aug 26, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·C C ChanS D Lee
Nov 9, 2000·European Journal of Pharmacology·K BagatéM Barthelmebs
Dec 4, 2001·European Journal of Pharmacology·C LoichotM Barthelmebs
Jun 9, 2000·Kidney International·N EndlichJ J Helwig
Aug 2, 2015·Cellular Signalling·Melissa A WasilewskiDouglas G Tilley
Aug 12, 2005·Journal of Biomolecular Screening·Richik N GhoshRobert H Oakley
May 5, 1999·Journal of Cardiovascular Pharmacology·T C Resta, B R Walker
Jan 13, 2018·Scientific Reports·Yan WillièreKerim Mutig
Mar 14, 2014·American Journal of Physiology. Renal Physiology·Nicholas G MossWilliam J Arendshorst

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.